EGFR and colorectal carcinoma: Because RAS mutations are assessed in the routine diagnosis of colorectal carcinoma to assign epidermal growth factor receptor (EGFR) blockade therapy [10], we selected cells that are either wild-type for KRAS (HT-29), or carry the G12D and G13D mutations (LS174T and LoVo, respectively).